Table 1. Baseline characteristics of 82 mCRC patients treated with adjuvant cetuximab.
| Characteristic | No. of patients | % |
|---|---|---|
| Median and range of age (years) | 61 (51–70) | |
| Gender | ||
| Male/female | 46/36 | 56.1%/43.9% |
| Location | ||
| Left/right colon/rectal | 25/27/30 | 30.5%/32.9%/36.6% |
| Treatment | ||
| Cetuximab + CapeOX | 8 | 9.76% |
| Cetuximab + CapeOX+AVASTIN | 2 | 2.43% |
| Cetuximab +FOLFIR1 | 19 | 23.17% |
| Cetuximab +FOLFIR1+AVASTIN | 1 | 1.22% |
| Cetuximab +FOLFIRI+ Capecitabine | 1 | 1.22% |
| Cetuximab+FOLFOX | 42 | 51.23% |
| Cetuximab+FOLFOX+FOLFIRI | 5 | 6.10% |
| Cetuximab+FOLFOX+AVASTIN | 1 | 1.22% |
| Cetuximab+Tegafur | 1 | 1.22% |
| Cetuximab+Capecitabine | 2 | 2.43% |
| Tumor response | ||
| CR/PR | 6/44 | 7.32%/53.66% |
| SD/PD | 15/17 | 18.29%/20.73% |
| FCGR2A H131R | ||
| HH/HR/RR | 33/44/5 | 40.24%/53.66%/6.10% |
| FCGR3A F158V | ||
| FF/FV/VV | 49/25/8 | 59.76%/30.49%/9.75% |
Abbreviation: mCRC: metastatic colorectal cancer; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; CapeOX: capecitabine plus oxaliplatin; FOLFIR1: 5-fluorouracil plus calcium folinate plus irinotecan; FOLFOX: 5-fluorouracil plus calcium folinate plus oxaliplatin.